NRSN logo

NeuroSense Therapeutics (NRSN) Cash From Financing

Annual CFF

$3.90 M
+$200.00 K+5.41%

December 1, 2023

Summary

Performance

1-Year Change

+5.41%

3-Year Change

+666.73%

5-Year Change

+174.88%

15-Year Change

+174.88%

NRSN Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

45.59%
NRSN annual cash flow from financing activities is higher than 45.59% of companies in Healthcare sector

High & Low

All-time High

$11.90 M
NRSN annual cash flow from financing activities is currently -67.27% below its historical high of $11.90 million

3-Year Low

$3.69 M
NRSN annual cash flow from financing activities is currently +5.41% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 1, 2023
NRSN previous annual earnings announcement was published on Dec 1, 2023

Next Annual Earnings Report Date

N/A
NRSN next annual earnings announcement has not yet been scheduled

OtherNRSNcash flowmetrics:

Annual CFI

$3.65 M
NRSN annual cash flow from investing activities is $3.65 million

Annual CFO

-$8.45 M
NRSN annual cash flow from operations is -$8.45 million

Annual FCF

-$8.48 M
NRSN annual free cash flow is -$8.48 million

Annual CAPEX

-
NRSN annual capital expenditures value is unknown

Quarterly CFF

N/A

September 1, 2024

Summary

Performance

3-Month Change

-

1-Year Change

-

3-Year Change

-

5-Year Change

-

NRSN Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$4.32 M
NRSN quarterly cash flow from financing activities is currently at an all-time high

3-Year Low

$3.71 M
NRSN quarterly cash flow from financing activities is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 1, 2024
NRSN previous earnings announcement was published on Sep 1, 2024

Next Quarterly Earnings Report Date

N/A
NRSN next earnings announcement has not yet been scheduled

OtherNRSNcash flowmetrics:

Quarterly CFI

-
NRSN quarterly cash flow from investing activities value is unknown

Quarterly CFO

-
NRSN quarterly cash flow from operations value is unknown

Quarterly FCF

-
NRSN quarterly free cash flow value is unknown

Quarterly CAPEX

-
NRSN quarterly capital expenditures value is unknown

TTM CFF

N/A

September 1, 2024

Summary

Performance

3-Month Change

-

1-Year Change

-

3-Year Change

-

5-Year Change

-

NRSN TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$4.32 M
NRSN TTM cash flow from financing activities is currently at an all-time high

3-Year Low

$3.71 M
NRSN TTM cash flow from financing activities is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 1, 2024
NRSN previous earnings announcement was published on Sep 1, 2024

Next Quarterly Earnings Report Date

N/A
NRSN next earnings announcement has not yet been scheduled

OtherNRSNcash flowmetrics:

TTM CFI

-
NRSN TTM cash flow from investing activities value is unknown

TTM CFO

-
NRSN TTM cash flow from operations value is unknown

TTM FCF

-
NRSN TTM free cash flow value is unknown

TTM CAPEX

-
NRSN TTM capital expenditures value is unknown

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

NRSN Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+5.4%--
3 y3 years+666.7%--
5 y5 years+174.9%--

NRSN Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-67.3%+5.4%
5 y5-year-67.3%+666.7%
alltimeall time-67.3%+666.7%

NeuroSense Therapeutics Cash From Financing History

DateAnnualQuarterlyTTM
Jun 2024
-
$4.32 M(+8.6%)
$4.32 M(+8.6%)
Dec 2023
$3.90 M(+5.4%)
-
-
Jun 2023
-
$3.98 M(+7.2%)
$3.98 M(+7.2%)
Dec 2022
$3.69 M(-69.0%)
-
-
Jun 2022
-
$3.71 M
$3.71 M
DateAnnualQuarterlyTTM
Dec 2021
$11.90 M(+2242.9%)
-
-
Jun 2021
-
$700.00 K(-100.0%)
-$5.57 B(-0.0%)
Mar 2021
-
-$5.57 B
-$5.57 B
Dec 2020
$508.00 K(-64.1%)
-
-
Dec 2019
$1.42 M
-
-

FAQ

  • What is NeuroSense Therapeutics annual cash flow from financing activities?
  • What is the all time high annual CFF for NeuroSense Therapeutics?
  • What is NeuroSense Therapeutics annual CFF year-on-year change?
  • What is the all time high quarterly CFF for NeuroSense Therapeutics?
  • What is the all time high TTM CFF for NeuroSense Therapeutics?

What is NeuroSense Therapeutics annual cash flow from financing activities?

The current annual CFF of NRSN is $3.90 M

What is the all time high annual CFF for NeuroSense Therapeutics?

NeuroSense Therapeutics all-time high annual cash flow from financing activities is $11.90 M

What is NeuroSense Therapeutics annual CFF year-on-year change?

Over the past year, NRSN annual cash flow from financing activities has changed by +$200.00 K (+5.41%)

What is the all time high quarterly CFF for NeuroSense Therapeutics?

NeuroSense Therapeutics all-time high quarterly cash flow from financing activities is $4.32 M

What is the all time high TTM CFF for NeuroSense Therapeutics?

NeuroSense Therapeutics all-time high TTM cash flow from financing activities is $4.32 M